Unicycive(US:UNCY) Prnewswireยท2025-09-11 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Unicycive Therapeutics overstated its readiness to meet FDA manufacturing compliance requirements, as well as the regulatory prospects of its oxylanthanum carbonate new drug application [1]. - It is claimed that the public statements made by the defendants were materially false and misleading throughout the class period from March 29, 2024, to June 27, 2025 [1]. Class Action Details - Shareholders who purchased shares of UNCY during the class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible business conduct [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].